Three-field or Two-field Resection for Thoracic Esophageal Cancer: a Meta-analysis
Overview
Pulmonary Medicine
Affiliations
Background: There have been many controversies about the optimal extent of lymphadenectomy for thoracic esophageal cancer, whether three-field lymphadenectomy is superior to two-field lymphadenectomy with respect to the 5-year survival rate and perioperative morbidities and mortality.
Methods: A comprehensive search of PubMed and Embase for relevant studies comparing three-field and two-field lymphadenectomies for thoracic esophageal cancer was conducted using the Preferred Reporting Items for Systemic Reviews and Meta-Analyses standards. Hazard ratios (HRs) were extracted from these studies to give pooled estimates of the effect of the two surgical procedures on the 5-year survival rate and perioperative morbidities and mortality.
Results: Thirteen studies were included for analysis. Compared with two-field lymphadenectomy, three-field lymphadenectomy provided a higher 5-year survival rate (HR 0.64, 95% confidence interval [CI]: 0.56 to 0.73, p = 0.000) and incidence of anastomotic leakage (HR 1.46, 95% CI: 1.19 to 1.79, p = 0.000), with a comparative perioperative mortality (HR 0.64, 95% CI: 0.38 to 1.10, p = 0.110) and incidence of vocal cord palsy (HR 1.12, 95% CI: 0.82 to 1.54, p = 0.470) and pulmonary complications (HR 1.00, 95% CI: 0.89 to 1.12, p = 0.760).
Conclusions: Published evidence indicated that three- field lymphadenectomy could be a priority for thoracic esophageal cancer, especially for tumors with positive lymph nodes. Given the lack of large-sample randomized controlled studies, further evaluations are necessary.
Huang X, Jiang S, Li Z, Lin X, Chen Z, Hu C Front Oncol. 2025; 14:1388355.
PMID: 40034253 PMC: 11872891. DOI: 10.3389/fonc.2024.1388355.
Liang J, Zhao Z, Xie Y, Lai D, Okereke I, Velotta J Transl Cancer Res. 2025; 14(1):613-625.
PMID: 39974376 PMC: 11833366. DOI: 10.21037/tcr-2024-2402.
Yuan P, Huang Z, Yang Y, Bao F, Sun K, Chao F Cancer Imaging. 2024; 24(1):153.
PMID: 39533388 PMC: 11556142. DOI: 10.1186/s40644-024-00799-0.
Sun Z, Fan B, Liu J, Di S, Yue C, Zhao J Transl Cancer Res. 2024; 13(7):3437-3445.
PMID: 39145057 PMC: 11319954. DOI: 10.21037/tcr-23-2356.
Florea I, Shersher D Ann Surg Oncol. 2024; 31(6):3584-3586.
PMID: 38494561 DOI: 10.1245/s10434-024-15176-1.